58
Participants
Start Date
August 30, 2016
Primary Completion Date
November 3, 2025
Study Completion Date
November 3, 2025
Tazemetostat
Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.
University Hospital (UZ) Leuven, Leuven
Peter MacCallum Cancer Institute, Melbourne
Monash Medical Centre- Monash Campus, Clayton
Columbia University Medical Center, New York
David H. Koch Center for Cancer Care at memorial Sloan Kettering Cancer Center, New York
CHU de Caen - Hôpital Côte de Nacre, Caen
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
Institut Bergonie, Bordeaux
Moffitt, Tampa
Hematology Oncology Associates of the Treasure Coast - Port St. Lucie, Port Saint Lucie
CHU Rennes- Hopital Pontchaillou, Rennes
University of Michigan, Ann Arbor
CHRU de Lile- Hopital Claude Huriez, Lille
"S.P. Grigoreva Institute of Medical Radiology and Oncology of NAMS of Ukraine", Kharkiv
Central Care Cancer Center, Bolivar
Centre Hospitalier Lyon Sud, Pierre-Bénite
Hôpital Saint Louis - AP-HP, Paris
Centre Henri Becquerel, Rouen
University of Arizona Cancer Center, Tucson
California Cancer Associates For Research And Excellence, cCARE, Santa Fe
Gustave Roussay, Villejuif
Dana-Farber Cancer Institute, Boston
Astera Cancer Center, East Brunswick
Princess Alexandra Hospital, Alexandra
Geelong Hospital, Geelong
Monash Health, Monash
CHU de Montpellier - Hopital Saint Eloi, Montpellier
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Endokrynologii Onkologicznej i Medycyny Nuklearnej, Warsaw
Beatson, West of Scotland Cancer Centre, Glasgow
The Christie NHS Foundation Trust, Manchester
Pratia MCM Krakow, Krakow
Oncology and Haematology Clinical Trials Unit, Leicester
Clatterbridge Cancer Centre, Liverpool
Hammersmith Hospital, London
Lead Sponsor
Epizyme, Inc.
INDUSTRY